Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
40.83
-0.14 (-0.34%)
At close: Feb 11, 2026, 4:00 PM EST
40.04
-0.79 (-1.93%)
After-hours: Feb 11, 2026, 7:09 PM EST
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Corcept Therapeutics stock have a consensus rating of "Buy" and an average price target of $114.2, which forecasts a 179.70% increase in the stock price over the next year. The lowest target is $95 and the highest is $150.
Price Target: $114.2 (+179.70%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $99 → $100 | Strong Buy | Maintains | $99 → $100 | +144.92% | Jan 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $105 | Strong Buy | Maintains | $90 → $105 | +157.16% | Jan 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $140 → $99 | Strong Buy | Maintains | $140 → $99 | +142.47% | Jan 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $145 → $90 | Strong Buy | Maintains | $145 → $90 | +120.43% | Jan 2, 2026 |
| UBS | UBS | Hold Initiates $95 | Hold | Initiates | $95 | +132.67% | Dec 16, 2025 |
Financial Forecast
Revenue This Year
830.91M
from 675.04M
Increased by 23.09%
Revenue Next Year
1.08B
from 830.91M
Increased by 29.62%
EPS This Year
0.95
from 1.23
Decreased by -22.74%
EPS Next Year
0.62
from 0.95
Decreased by -34.88%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 866.3M | 1.3B | ||||
| Avg | 830.9M | 1.1B | ||||
| Low | 786.7M | 826.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 28.3% | 59.6% | ||||
| Avg | 23.1% | 29.6% | ||||
| Low | 16.5% | -0.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.24 | 1.50 | ||||
| Avg | 0.95 | 0.62 | ||||
| Low | 0.79 | -0.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.7% | 58.0% | ||||
| Avg | -22.7% | -34.9% | ||||
| Low | -35.5% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.